Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CFD | P00746 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12965912 | 1.00 | CYP3A4 (0.60) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19334151 | 0.91 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12159633 | 0.91 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12159637 | 0.91 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL14479577 | 0.91 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL14216970 | 0.91 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL10072004 | 0.91 | CYP3A4 (0.61) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19521710 | 0.89 | CYP3A4 (0.65) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3342392 | 0.88 | CYP3A4 (0.67) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3343983 | 0.88 | CYP3A4 (0.67) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139569-B2 | Fused tricyclic aryl compounds useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, AADAC | CYP3A4 168/4885CYP2C9 630/4885KCNH2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.